Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
January 12, 2016Esperion announced initiation of a Phase 2 pharmacokinetics/pharmacodynamics study of bempedoic acid in patients treated with atorvastatin 80 mg. The Company expects to announce top-line results from the study by mid-year.
More »
Five Prime Therapeutics Provides Update on FP-1039 Clinical Program
January 11, 2016If Five Prime sees positive results from an increased enrollment in arm C, they will seek to regain rights for FP-1039 in the U.S., Canada and the E.U. from GSK, as mesothelioma could represent a potentially attractive market opportunity.
More »
Achaogen Announces Enrollment of First Patient in EPIC, a Phase 3 Clinical Trial for the Treatment of Complicated Urinary Tract Infections (cUTI) With Plazomicin
January 11, 2016The EPIC study is part of Achaogen’s strategy to expedite the path to market for plazomicin. Enrollment in Cohort 2 of the CARE study reflects the ongoing commitment to generate clinical data for plazomicin in treatment of patients with CRE infections.
More »